Key Takeaways Semaglutide produces clinically significant weight loss the STEP 1 trial demonstrated a mean 14.9% body weight reduction at 68 weeks with the 2.4 mg dose The dose escalation schedule is medically necessary, not optional rushing it leads to severe GI side effects that cause most treatment discontinuations Semaglutide is a long-term medication weight returns if treatment is stopped, as shown in the STEP 1 extension trial It carries real contraindications including a family history of medullary thyroid carcinoma, MEN2, pregnancy, and severe GI disease Drug interactions with oral medications are clinically relevant your full medication list must be reviewed by a pharmacist or physician before starting Maximum benefit requires combining semaglutide with a healthy diet and physical activity it reduces appetite, but it does not replace lifestyle modification References Wilding JPH, Batterham RL, Calanna S, et al
294 , E576E581 (2008)
doi: 10.1038/s41580-020-00324-8 27 DixonSJLembergKMLamprechtMRSkoutaRZaitsevEMGleasonCEet al
undernutrition states post-operative, post-infection, post-trauma, post-chemotherapy, chronic respiratory insufficiency, the elderly, the newborn prediabetics or diabetics hyperlipemia or in the treatment of heart disease (angina, heart failure), liver failure, cirrhosis
Some had progressive loss of vision
In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at maternal exposures below the maximum recommended human dose (MRHD) based on AUC